Allergy Labels Linked to Adverse Birth Outcomes

- The study analyzed over 2.2 million singleton live births in California between 2016 and 2021, identifying 10,460 mothers with a non-narcotic analgesics allergy label (NNAAL). - Researchers suggest that approximately 80% of these allergy labels could be inaccurate and that a proactive evaluation to "delabel" patients could lead to better perinatal outcomes. - One significant consequence of an NNAAL is increased opioid use; a separate study found that pregnant individuals with this label were more likely to receive opioids for postpartum pain and at higher doses. This aligns with the original study's finding of an increased risk for neonatal withdrawal syndrome in infants born to mothers with an NNAAL. - Up to 2.5% of women of childbearing age report an allergy to nonsteroidal anti-inflammatory drugs (NSAIDs), which can be a barrier to their use for both pain management and the prevention of preeclampsia. - The avoidance of NSAIDs, such as aspirin, is particularly concerning as low-dose aspirin is recommended for the prevention of preeclampsia in high-risk pregnancies. The study found a 1.5 times increased risk of eclampsia in patients with an NNAAL. - The U.S. Food and Drug Administration (FDA) advises against the use of NSAIDs at 20 weeks of pregnancy or later due to the risk of rare but serious kidney problems in the fetus, which can lead to low amniotic fluid. This recommendation adds another layer of complexity to pain management during pregnancy. - For postpartum pain, national guidelines recommend a stepwise approach that begins with non-opioid analgesics like NSAIDs, with opioids reserved for when these are insufficient. - In Virginia, organizations such as the Virginia Neonatal Perinatal Collaborative are working to address maternal mortality and improve perinatal care through data-driven initiatives and collaboration with healthcare providers and community organizations.